Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study

Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/36382

Title:	Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Authors:	SCARISBRICK, Julia; HORWITZ, Steven M.; PRINCE, H. Miles; WHITTAKER, Sean; DUVIC, Madeleine; KIM, Youn H.; QUAGLINO, Pietro; ZINZANI, Pier Luigi; BECHTER, Oliver; ERADAT, Herbert; PINTER-BROWN, Lauren; AKILOV, Oleg; GESKIN, Larisa; SANCHES, Jose; ORTIZ-ROMERO, Pablo; LISANO, Julie; BROWN, Lisa; BUNN, Veronica; LITTLE, Meredith; DUMMER, Reinhard
Citation:	EUROPEAN JOURNAL OF CANCER, v.119, suppl.1, p.S31-S31, 2019
Appears in Collections:	Comunicações em Eventos - FM/MDT Departamento de Dermatologia - FM/MDT Comunicações em Eventos - HC/ICHC Instituto Central - HC/ICHC Comunicações em Eventos - LIM/53 LIM/53 - Laboratório de Micologia

Files in This Item:

There are no files associated with this item.